Thermo Fisher Scientific Stock News

On Friday, the FDA published a list of molecular tests for COVID-19 that may be affected by mutations in the omicron variant of concern. The agency's list focuses on coronavirus tests impacted by S-

The Cytotoxicity assays measure the loss of some cellular or intercellular structure and/or functions, counting lethal cytotoxicity. They thus give a suggestion of the possibility to cause cell and matter injury and as such has been used by some detectives

According to the new market research report "Flow Cytometry Market by Product (Analyzer, Sorter, Reagents, Consumables, Software), Technology, Application (Research, Clinical - Cancer Diagnostics, Hematology), End User (Academia, Research Labs, Pharma, Biotech, Hospitals) - Global Forecast to 2026", published by

Key Players Covered in the Point of Care Diagnostics Market Research Report Are F. Hoffmann-La Roche Ltd (Basel, Switzerland), Thermo Fisher Scientific Inc. (Massachusetts, U.S.), Abbott Laboratories (Illinois, U.S), Quest Diagnostics Incorporated (New Jersey, United States), BD (Franklin Lakes, U.S), bioMérieux SA (Marcy l''Etoile, France), Cardinal Health, Inc. (Ohio, U.S), Mesa Biotech (California, U.S), Cepheid (California, U.S), Trinity Biotech (Bray, Ireland), Quidel Corporation (San Diego, U.S.), Bio-Rad Laboratories Inc. (California, U.S) and other key market players Key Players Covered in the Point of Care Diagnostics Market Research Report Are F. Hoffmann-La Roche Ltd (Basel, Switzerland), Thermo Fisher Scientific Inc. (Massachusetts, U.S.), Abbott Laboratories (Illinois, U.S), Quest Diagnostics Incorporated (New Jersey, United States), BD (Franklin Lakes, U.S), bioMérieux SA (Marcy l''Etoile, France), Cardinal Health, Inc. (Ohio, U.S), Mesa Biotech (California, U.S), Cepheid (California, U.

Pune , India , 2021-Dec-07 /EPR Network/ The global In-vitro diagnostics market size is projected to reach USD 96.0 billion by 2025 from [read full press release]

MISE & Agrave; DAY Merck Canada announced Monday that it has reached an agreement with Ontarian Thermo Fisher Scientific to manufacture molnupiravir, an experimental oral antiviral drug against COVID-19. If approved for use by regulatory authorities, Merck hopes to make the drug available globally. Thermo Fisher, located in Whitby, Ont., Will produce molnupiravir with a [] The post Oral treatment for COVID-19: Merck prepares for global distribution first appeared on The Bobr Times .

Douglas Lane & Associates LLC lowered its stake in Thermo Fisher Scientific Inc. (NYSE:TMO) by 2.4% in the 3rd quarter, Holdings Channel.com reports. The firm owned 250,257 shares of the medical research companys stock after selling 6,212 shares during the period. Thermo Fisher Scientific makes up 2.0% of Douglas Lane & Associates LLCs holdings, making []

Venture Visionary Partners LLC increased its holdings in shares of Thermo Fisher Scientific Inc. (NYSE:TMO) by 1.9% in the 3rd quarter, HoldingsChannel.com reports. The firm owned 3,356 shares of the medical research companys stock after acquiring an additional 61 shares during the period. Venture Visionary Partners LLCs holdings in Thermo Fisher Scientific were worth $1,920,000 []

Merck Canada is partnering with Thermo Fisher Scientific to manufacture Mercks antiviral drug molnupiravir at a facility in Whitby, Ont., for distribution to global markets, the company announced on Monday.

The Global Serum Freezing Culture Media Market report offers a comprehensive evaluation of the market. It does give in-depth analysis via qualitative insights, historical data, and verifiable projections about market size. The projections featured in the report have been derived

Thermo Fisher's (TMO) ReadyCheckGo program will enable Texas schools to have the options for fast, reliable testing to identify and limit the spread of COVID-19 quickly.

1776 Wealth LLC cut its stake in Thermo Fisher Scientific Inc. (NYSE:TMO) by 34.1% during the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 974 shares of the medical research companys stock after selling 503 shares during the quarter. 1776 Wealth LLCs holdings []